An evaluation of postmarketing reports of hyperglycaemia associated with dolutegravir for treatment of HIV in Eswatini

Alemayehu L. Duga1,2,3*, Sibongile Magongo1, Siphesihle Nhlabatsi2, Denis O. Ladwar4, Linda Härmark5 and Leàn Rolfes5

Abstract

Background: Dolutegravir (DTG) is an Integrase Strand Transfer Inhibitor (INSTI) indicated in combination with other antiretroviral agents for the treatment of HIV infection. It is available in a number of pharmaceutical preparations including the fixed-dose combination (TLD) containing tenofovir (300 mg) + lamivudine (300 mg) + dolutegravir (50 mg). In 2018, Eswatini adopted TLD as the preferred first-line HIV treatment regimen for adults and adolescents as per WHO recommendations. From March 2019 to March 2020, the National Pharmacovigilance Center (NPC) in Eswatini received 8 reports of hyperglycaemia associated with the use of DTG. This study was conducted to investigate if Eswatini NPC database included cases suggestive of causality between dolutegravir and hyperglycaemia.

Method: A qualitative synthesis of information from the Eswatini national pharmacovigilance database from March 2019 to March 2020 was conducted to investigate a causal association between hyperglycaemia and dolutegravir.

Results: All reports with dolutegravir containing regimen and suspected Adverse Event of hyperglycaemia in the period of March 2019 to March 2020 were included in the study. Seven of the reports were serious (resulted in hospitalization and one case concerned optic neuritis, leading to blindness). Two patients had a medical history of diabetes while the rest of the patients had never experienced hyperglycaemia before starting dolutegravir. For all the reports, the time to onset of hyperglycaemia ranges from 2–5 months after the initiation of DTG. None of the patients discontinued the use of DTG. All the patients were treated with oral hypoglycaemic medication. In severe cases, patients were treated with intravenous normal saline and ringer lactate as well as rapid-acting insulins. All patients are currently stable on oral hypoglycaemic drugs.

Conclusion: Cases that support causality between dolutegravir containing regimen and hyperglycaemia were found. These cases were mainly serious. Based on these findings it is recommended that healthcare professionals (HCPs) actively screen all patients for risk factors of hyperglycaemia before DTG initiation. In addition, it is important that HCPs are aware of the possible association between DTG and hyperglycaemia.

Keywords: Dolutegravir, HIV/AIDS, Eswatini, Hyperglycaemia, Pharmacovigilance, Signal

Background

Since the approval of zidovudine (AZT) in 1987, more than 25 antiretroviral agents in six classes have been approved to treat HIV infection [1]. These include nucleoside reverse transcriptase inhibitors (NRTIs), nucleotide reverse transcriptase inhibitors (NtRTIs),
non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), fusion inhibitors (FIs), and integrase inhibitors (INSTIs) [2]. Dolutegravir is a new INSTI approved for combination treatment in HIV-infected patients [3]. In 2013, the U.S. Food and Drug Administration approved dolutegravir (Tivicay®) tablets, in combination with other antiretroviral agents for the treatment of HIV infection in adults and children aged 12 years and older and weighing at least 40 kg [4]. It was also added to the 20th edition of the World Health Organization (WHO) Essential Medicine List in 2017 [5]. It is available as mono and fixed-dose combination (TLD), together with tenofovir (TDF) and lamivudine (3TC).

TDF belongs to a class of antiretroviral drugs known as nucleotide analogue reverse transcriptase inhibitors (NtRTIs), which block reverse transcriptase, an enzyme necessary for viral production in HIV-infected individuals [6]. 3TC is a nucleoside analogue which is incorporated into viral DNA by HIV reverse transcriptase and HBV polymerase, resulting in DNA chain termination, while DTG inhibits HIV integrase by binding to the active site and block the strand transfer step of retroviral DNA integration in the host cell [7, 8].

In Eswatini the first-line treatment for HIV is a fixed-dose combination (TLD), which contains TDF 300 mg + 3TC 300 mg + DTG 50 mg. The fixed-dose combination is available in the form of tablets for adults and adolescents. Due to DTG’s high viral suppression abilities, newer paediatric formulations containing 25 mg and 10 mg DTG are being developed and are due to become available in the latter half of 2021 [9].

The Eswatini National AIDS Programme adopted the TLD regimen as the preferred first-line HIV treatment regimen for adults and adolescents in the country as per WHO recommendations in 2018 [10, 11]. This policy change initiated a transition of approximately 80% of the over 191,000 people living with HIV (PLHIV) on efavirenz (EFV) and nevirapine (NVP) based regimens to DTG based regimens in the period October 2018 to March 2020. Currently, over 68% of PLHIV are on TLD and other DTG containing regimens [12].

Known adverse drug reactions (ADRs) in relation to DTG are insomnia, nausea, diarrhoea, dizziness, and headache [11, 13]. The National Pharmacovigilance Center (NPC) in Eswatini received 8 reports of hyperglycaemia associated with the use of DTG from March 2019 to March 2020. Hyperglycaemia can cause severe implications for the patient. Timely recognition and treatment is necessary. This case series assessment aims to describe the cases and the possible relation between treatment with DTG and the occurrence of hyperglycaemia in Eswatini.

Methods

Pharmacovigilance reports were identified from the Eswatini national pharmacovigilance database from March 2019 (introduction of DTG) to March 2020. All reports with DTG containing regimen and suspected AE of hyperglycaemia in the period of March 2019 to March 2020 were included in the study. In addition, Africa (continental) and global cases were extracted from Vigibase, the WHO global database of individual case safety reports, using MedDRA [14] preferred terms (Hyperglycaemia/new onset Diabetes mellitus and Diabetes) as a search criteria which were used to support the in-country data. A qualitative descriptive analysis was then performed on the eligible reports from the database. The reports were then stratified by sex (male, female), age and seriousness (serious and non-serious). Excel were utilized for data cleaning and data analysis.

Results

The NPC analysed in-country reports in relation to DTG-containing regimen submitted in the period of March 2019 to March 2020. The Center received a total of 115 reports on DTG of which 8 reports were in relation hyperglycaemia. In global view, 961 reports out of 10,600 total reports on DTG containing regimens were hyperglycaemic cases; similarly 272 reports out of 1,233 reported in Africa are DTG-hyperglycaemia associated cases Hyperglycaemia is blood glucose greater than 7 mmol/l while fasting and greater than 10 mmol/l two hours postprandial [15]. All the patients included in the report are above 50 years of age, 6 were females and 2 males. None of the patients were discontinued from the DTG containing treatment nor the dose of DTG was changed and all patients were recovering from the hyperglycaemia after treatment with anti-diabetic treatment.

Seven of the cases were serious with six resulted in hospitalizations and one case of optic neuritis leading to blindness. Out of the 8 cases, 2 cases had a medical history of diabetes while the rest of the reports were newly diagnosed. For all the reports, the time to onset of the reaction ranges from 2–5 months after the initiation of the treatment. All of the patients were treated with oral hypoglycaemic medication to lower the blood glucose level. In severe cases, patients were treated with IV normal saline, ringer lactate as well as rapid-acting insulins. All patients are currently stable on hypoglycaemic drugs. Table 1 shows the eight hyperglycaemic cases attributed to DTG and DTG containing regimen.

Discussion

As with many new medicines, post market surveillance of DTG on a large scale is very important to establish its full safety and side effect profile. This case series

---

**Table 1:**

| Hyperglycaemia Case | Time to Onset | Patient Age | Sex | Diabetes History |
|---------------------|--------------|-------------|-----|-----------------|
| Case 1              | 2 months     | 52          | F   | Yes             |
| Case 2              | 3 months     | 55          | M   | No              |
| Case 3              | 4 months     | 60          | F   | Yes             |
| Case 4              | 5 months     | 63          | M   | No              |
| Case 5              | 6 months     | 58          | F   | Yes             |
| Case 6              | 7 months     | 57          | M   | No              |
| Case 7              | 8 months     | 62          | F   | Yes             |
| Case 8              | 9 months     | 59          | M   | No              |
contributes to the knowledge about the possible association of hyperglycaemia and DTG treatment. Known factors contributing to hyperglycaemia include reduced insulin secretion, decreased glucose utilization, and increased glucose production, and several medicine, like antihypertensive drugs and protease inhibitors [15]. Additionally, factors like advancing age, male gender, longer duration of HIV infection, low CD4 count, high viral burden, high body mass index, obesity, lower socioeconomic class, comorbidity and drugs should be taking into consideration as contributing factors for hyperglycaemia when it occurs in patient on DTG [16].

A few clinical trial studies and review papers strengthen the evidence that integrase inhibitors (the drug class that DTG belongs to) can induce hyperglycaemia [17, 18]. According to VIKING-3, a single armed phase III clinical trial, hyperglycaemia was one of the most common laboratory abnormalities in 14% of the patients at week 48 of integrase strand transfer inhibitor therapy [17].

Table 1 List of hyperglycaemic cases

| Sex and age | a.Suspected drug | b.Strength | c.Frequency of administration | d.Indication | Treatment of ADR | Concomitant ADR | ADR reported | Serious and seriousness criteria | Time to onset | Outcome of the ADR |
|-------------|------------------|------------|-----------------------------|--------------|-----------------|----------------|--------------|-------------------------------|--------------|----------------------|
| Female, 51  | a.Dolutegravir; Lamivudine; Tenofovir | b.50 mg/300 mg/300 mg | c.Once a day | d.HIV infection | Metformin 500 mg | Isoniazid | Hyperglycaemia | Yes; hospitalization | 5 months | Recovering |
| Female, 52  | a.Dolutegravir; Lamivudine; Tenofovir | b.50/300 mg/300 mg | c.Once day | d.HIV infection | Metformin 500 mg and Glibenclamide 5 mg | | Hyperglycaemia | Yes; hospitalization | 2 months | Recovering |
| Male, 64    | a.Abacavir; Dolutegravir; Lamivudine | b.Once a day | c.HIV infection | | 1. Insulin and normal saline 2.Metformin 500 mg | | Hyperglycaemia Blindness | Yes; hospitalization | 4 months | Recovering |
| Female, 52  | a.Dolutegravir; Lamivudine; Tenofovir | b.50 mg/300 mg/300 mg | c.Once a day | d.HIV infection | Continued with Metformin and Glibenclamide | Metformin Glibenclamide | Hyperglycaemia Muscle spasms Dizziness | Yes; hospitalization | 3 months | Recovering |
| Female, 57  | a.Dolutegravir; Lamivudine; Tenofovir | b.50 mg/300 mg/300 mg | c.Once a day | d.HIV infection | Metformin 500 mg | Hydrochlorothiazide Acetylsalicylic acid | Hyperglycaemia | Yes; hospitalization | 4 months | Recovering |
| Female, 70  | a.Dolutegravir; Lamivudine; Tenofovir | b.50 mg/300 mg/300 mg | c.Once a day | d.HIV infection | Metformin 500 mg | Atenolol Hydrochlorothiazide | Hyperglycaemia Muscle spasms | Yes; hospitalization | 3 months | Recovering |
| Male, 58    | a.Dolutegravir; Lamivudine; Tenofovir | b.50 mg/300 mg/300 mg | c.Once a day | d.HIV infection | Continued with Metformin 500 mg | Metformin 500 mg | Hyperglycaemia Muscle spasms | No | 3 months | Recovering |
| Female     | a.Dolutegravir; Lamivudine; Tenofovir | b.50 mg/300 mg/300 mg | c.Once a day | d.HIV infection | •Insulin 12 IU infused with ringer lactate solution •Metformin 500 mg •Glibenclamide 5 mg | Hydrochlorothiazide Enalapril | Hyperglycaemia | Yes; hospitalization | 5 months | Recovering |
A case–control study on the incidence of DTG-associated hyperglycaemia in patients with HIV from Uganda also indicates that patients who were transitioned to DTG-based first-line regimens had a higher incidence (16 (0.47%) of 3417 patients) of hyperglycaemia than patients who did not transitioned to DTG 1(0.03%) of 3230 patients in the control group (p = 0.0004) [18]. In literature, there are also a few case reports that support this association. For all the reports, the time to onset of the reaction ranges from 2–5 months after the initiation of the treatment. that has similarities with a study conducted in Uganda which indicates the mean onset of the ADR as 4 months [18]. In a case report, a patient presented to the emergency department (ED) with hyperglycaemia approximately 3 weeks after the switch from EFV to DTG [19].

In contrast to the above findings, the investigation from 4 DTG clinical trials (SPRING-1, STRIVING, SWORD-1 and -2) on the potential effect of DTG on insulin resistance over time found no association between treatment and insulin resistance observed over a 48 week period [20].

A mechanism for the DTG induced hyperglycaemia is not well understood. However, chelation of magnesium that inhibits the release and signalling of insulin was hypothesized as a mechanism of the toxicity [19]. According to the update of recommendations on first- and second-line antiretroviral regimens issued by the WHO, there is between 3 and 5 kg of unintentional weight gain in individuals receiving DTG-based regimens at 48 weeks, however nothing has been mentioned about hyperglycaemia in relation to the treatment in the update [21]. Hyperglycaemia and weight gain related to DTG are published in the FDA Product information based on clinical trial and post marketing surveillance studies [22]. However, the ADRs are not listed in the Summary of Product Characteristics (SmPC) of the European Medicines Agency (EMA) [23].

The NPC has not received hyperglycaemic cases associated to other HIV medicines during the review period. The SmPC of lamivudine does however include the occurrence of increase in weight and in levels of blood lipids and glucose [23]. Another study on a cohort of 533 HIV-infected and 755 HIV-seronegative men in the Multicentre AIDS Cohort Study evaluated indicates that insulin resistance was seen more commonly among patients with longer exposure to NRTI, in older patients, and in non-white patients [24]. Therefore, longer NRTI exposure could have an additive effect to the DTG hyperglycaemic property. The findings of this research will create an opportunity to improve future research on this area and contribute further understanding on DTG-hyperglycaemia association.

**Limitation of the study**

There could be under reporting of the cases as the case series study was analysed from the ADR reports reported to the pharmacovigilance center, which may not reflect the true picture of the hyperglycaemia cases caused by DTG in the whole country.

**Conclusion**

This case series contributes to knowledge about the possible association between the use of DTG and hyperglycaemia. Based on the cases received by the NPC and supporting information from VigiBase and literature, we consider hyperglycaemia to be a potential side effect of DTG. The hyperglycaemia can however successfully be treated with oral antidiabetic drugs while continuing DTG treatment. We would also like to emphasize that the necessity of awareness creation for health care workers and patients on the timely recognition of hyperglycaemic cases while on this treatment. Close monitoring of serum plasma glucose should be considered after the initiation of an INSTI.

**Abbreviations**

3TC: Lamivudine; ABC: Abacavir; DTG: Dolutegravir; EFV: Efavirenz; EMA: European medicine agency; HBV: Hepatitis B virus; ICSRs: Individual case safety reports; LPV/r: Lopinavir/Ritonavir; NVP: Nevirapine; PLHIV: People living with HIV; RBS: Random blood sugar; TDF: Tenofovir; TLD: Tenofovir, Lamivudine and Dolutegravir.

**Acknowledgements**

The authors wish to acknowledge the Eswatini Ministry of Health for human resource support and Pharmacovigilance Africa (PAVIA) project for their financial support in the development of this paper.

**Author contributions**

All authors contributed to the study conception and design. Literature review and data analysis were performed by Alemayehu L. Duga, Siphelele Nhlabati, Sibongile Magongo, Denis O. Ladwaa, Linda Harmark and Leän Rolfes. The first draft of the manuscript was written by Alemayehu Duga and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

**Funding**

LH, LR contribution to this paper was funded by the PAVIA Project, which is part of the EDCTP2 programme supported by the European Union (1627 PAVIA CSA20165). The views and opinions of authors expressed herein do not necessarily state or reflect those of EDCTP.

**Availability of data and materials**

Data belong to the Kingdom of Eswatini Ministry of Health (MoH). The MoH reserves the right to review and approve of all public health data before it is released to the public. Therefore, the authors of this manuscript do not have the right to make all the data underlying the manuscript fully available and without restrictions. Permission to access data needs to be requested in writing from the MoH.
Declarations

Ethics approval and consent to participate
This study was conducted retrospectively from Pharmacovigilance report obtained for clinical purposes. Ethical approval was obtained from Eswatini Health and Human Research Review Board (HHRRB) on January 26, 2021 with reference number of SHR274/2020.

Consent for publication
Not applicable.

Competing interests
The authors have declared that no competing interests exist.

Author details
1 Medicine Regulatory Unit, Eswatini Ministry of Health, Matsapha, Eswatini. 2 National Pharmacovigilance Center, Eswatini Ministry of Health, Matsapha, Eswatini. Baylor College of Medicine Children’s Foundation, Mbabane, Eswatini. 3 Chemonics Eswatini, Manzini, Eswatini. 4 The Netherlands Pharmacovigilance Center Lareb, s-Hertogenbosch, The Netherlands.

Received: 13 April 2022   Accepted: 9 November 2022
Published online: 24 November 2022

References

1. Cihlar T, Fordyce M. Current status and prospects of HIV treatment. Curr Opin Virol. 2016. https://doi.org/10.1016/j.coovi.2016.03.004.
2. De Clercq E. Antiretroviral drugs. Curr Opin Pharmacol. 2010;10:507–15.
3. Rathbun RC, Lockhart SM, Miller MM, Liedtke MD. Dolutegravir, a second-generation integrase inhibitor for the treatment of HIV-1 infection. Ann Pharmacother. 2014;48:395–403.
4. USFDA. Drug Approval Package: Brand Name (Generic Name) NDA # [Internet]. 2018. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204790Orig1s000TOC.cfm. Accessed 14 Apr 2021.
5. World Health Organization. WHO Model List of Essential Medicines. 2017. http://www.who.int/medicines/publications/essentialmedicines/en/. Accessed 18 May 2020.
6. Duwal S, Schütte C, von Kleist M. Pharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infection. PLoS One. 2012. https://doi.org/10.1371/journal.pone.0040382.
7. Min S, Song J, Borland J, Chen S, Lou Y, Fujiwara T, et al. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother. 2010;54(12):254–8.
8. Cihlar T, Ray AS. Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine. Antivir Res. 2010;87–9.
9. Dolutegravir | Integrate Inhibitors | Pediatric ARV | AIDSinfo. https://aidsinfo.nih.gov/guidelines/html/2/pediatric-arv/435/dolutegravir. Accessed 1 Jun 2020.
10. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV supplement to the 2016 consolidated guidelines on the use of antiretroviral drugs for treating. 2018.
11. The Kingdom of Eswatini M of H. 2018 Eswatini Integrated HIV Management Guidelines. Mbabane; 2018.
12. The Kingdom of Eswatini M of H. LMIS data. Mbabane; 2020.
13. FDA. Dolutegravir | FDA Label - Tablet (film coated) | AIDSinfo. https://aidsinfo.nih.gov/drugs/509/dolutegravir/167/professional#invalid_link. Accessed 28 May 2020.
14. ICH. ICH Official web site : ICH History. 2020. https://www.ich.org/page/meddra. Accessed 15 Apr 2021.
15. Suri P, Aurora T. Hyperglycemia. In: Observation Medicine: Principles and Protocols. Cambridge University Press; 2017. p. 225–30.
16. Kalra S, Kalra B, Agrawal N, Unnikrishnan A. Understanding diabetes in patients with HIV/AIDS diabetology and metabolic syndrome. BioMed Central. 2011. https://doi.org/10.1186/1758-5966-3-2.
17. Brewer JP. Research Triangle Park [Internet]. Vol. 368, Nature. 1994. www.fda.gov/medwatch. & May 2020.
18. Lamorde M, Atwiine M, Owarwo NC, Ddungu A, Laker EO, Mubiru F, et al. Dolutegravir-associated hyperglycaemia in patients with HIV. Lancet HIV. 2020. https://doi.org/10.1016/S2352-3018(20)30042-4.
19. McLaughlin M, Walsh S, Galvin S. Dolutegravir-induced hyperglycaemia in a patient living with HIV. J Antimicrob Chemother. 2018;73:558–60.
20. Janet Lo et al. DOLUTEGRAVIR AND INSULIN RESISTANCE—CROI Conference. Conference on Retroviruses and Opportunistic Infections; 2019. https://www.croiconference.org/abstract/dolutegravir-and-insulin-resistance/. 8 May 2020.
21. World Health Organization. Update of recommendations on first- and second-line antiretroviral regimens. 2019. http://apps.who.int/bookorders. 17 May 2020.
22. FDA. Highlights of Prescribing information. 2013. www.fda.gov/medwatch. 17 May 2020.
23. EMA. Summary of product characteristics. In: Pharmaceutical Medicine. 2014. p. 87–9.
24. Brown TT, Li X, Cole SR, Kingsley LA, Palella FJ, Riddler SA, et al. Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the multicenter AIDS cohort study. AIDS. 2005;21(13):1375–83.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions